



Editor-in-Chief
Pedro T Ramirez (USA)

Associate Editors
Anna Fagotti (Italy)
Michael Frumovitz (USA)
Rene Pareja (Colombia)
Anuja Jhingran (USA)

Video Editor
Luis Chiva (Spain)

Social Media Editors
Andreina Fernandes (Venezuela)
Aarthi S. Jayraj (United Kingdom)

Managing Editor
Emily Hammond (USA)

Editorial Office
International Journal of Gynecological Cancer, BMJ Journals
Two Hudson Square, 3rd Floor,
Hoboken, NJ 07030 USA
E: ijgc@bjeditorial.com

Production Editor
Hannah Martin
E: production.ijgc@bmj.com

Customer support
For general queries and support with
existing and new subscriptions:
W: support.bmj.com
T: +44 (0)20 7111 1105
E: support@bmj.com

Self-archiving and permissions
W: bmj.com/company/products-services/rights-and-licensing/
E: bmj.permissions@bmj.com

Disclaimer: The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

Copyright: © 2023 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced in any form without permission.

The *International Journal of Gynecological Cancer* (IJGC) is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

Lead Article

- 431** Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions
G Caruso, F Tوماو, G Parma, M Lapresa, F Multinu, I Palaia, G Aletti, N Colombo

Editorial

- 444** PARP inhibitor era: current status and future directions
R L Coleman

Consensus Statement

- 446** The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia
V Kesic, X Carcopino, M Preti, P Vieira-Baptista, F Bevilacqua, J Bornstein, C Chargari, M Cruickshank, E Erzenoglu, N Gallio, M Gultekin, D Heller, E Joura, M Kyrgiou, T Madić, F Planchamp, S Regauer, O Reich, B Esat Temiz, L Woelber, J Zdzicka, C Stockdale

Society statement

- 462** ESGO Prevention Committee opinion: is a single dose of HPV vaccine good enough?
M O Kamani, M Kyrgiou, E Joura, I Zapardiel, M Grigore, M Arbyn, M Preti, F Planchamp, M Gultekin

Vulvar Cancer

- 465** The modified 5-item frailty index is a predictor of post-operative complications in vulvar cancer: a National Surgical Quality Improvement Program (NSQIP) analysis
M D Levine, A S Felix, C E Meade, K L Bixel, L M Chambers
- 473** Electrochemotherapy with intravenous bleomycin for heavily pre-treated vulvar cancer patients
A M Perrone, G Corrado, C A Coad, G Garganese, S M Fragomeni, L Tagliaferri, S Di Costanzo, E De Crescenzo, A G Morganti, M Ferioli, F De Terlizzi, G Scambia, P De Iaco

Cervical Cancer

- 482** Microbiota unbalance in relation to high-risk human papillomavirus cervical infection
J F Gomez Cherey, S N Payalef, L Fleider, A P Reyes, V A Maldonado, M O Losada, X Chen, L H Cardinal, Y Wang, S A Tatti, B E Perazzi
- 489** Human papillomavirus independent status on pathologic response and outcomes in locally advanced cervical cancer managed with chemoradiotherapy followed by surgery
L C Turco, L Pedone Anchora, C Fedele, F Inzani, A Piermattei, M Martini, M Volpe, S Marchetti, R Santangelo, N Bizzarri, F Cosentino, V Vargiu, M De Ninno, G Macchia, V Valentini, G Zannoni, G Scambia, G Ferrandina
- 498** Proof-of-concept randomized phase II non-inferiority trial of simple versus type B2 hysterectomy in early-stage cervical cancer ≤2 cm (LESSER)
V C G Carneiro, T P Batista, M R Andrade, A V Barros, L H L D Câmara, N M Ramalho, M A Lucena, D F S Fontão, R Tancredi, T C Silva Júnior, A L R Bezerra, G Baiocchi

Uterine Cancer

- 504** Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer
B L Hill, R P Graf, K Shah, N Danziger, D I Lin, J Quintanilha, G Li, J Haberberger, J S Ross, A D Santin, B Slomovitz, J A Elvin, R N Eskander
- 514** Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: a retrospective single-center experience
V Salutari, V Ghizzoni, M V Carbone, E Giudice, S Cappuccio, F Fanfani, G Scambia, D Lorusso
- 521** Laparoscopic sentinel lymph node mapping with indocyanine green in endometrial cancer: surgeon's learning curve (cumulative sum analysis)
M Gedgaudaite, S Paskauskas, A Bartusevicius, J Celiesiute, E Svedas, D Vaitkiene, E Drejeriene, A Inciura, A Gaurilcikas

- 528** Prehabilitation in an ERAS program for endometrial cancer patients: impact on post-operative recovery

E Miralpeix, B Fabregó, C Rodríguez-Cosmen, J-M Solé-Sedeño, S Gayete, D Jara-Bogunya, M Corcoy, G Mancebo

Ovarian Cancer

- 534** Case-mix adjustment to compare hospital performances regarding complications after cytoreductive surgery for ovarian cancer: a nationwide population-based study

M D Algera, N M S Baldewpersad Tewarie, W J van Driel, M A P C van Ham, B F M Slangen, R F P M Kruitwagen, M W J M Wouters, Participants of the Dutch Gynecological Oncology Audit Collaborator Group

- 543** Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumab

L Verleye, D Castanares-Zapatero, C Devos, C De Gendt, G Silversmit, N Van Damme, F Hulstaert, N Thiry, M Neyt

- 549** Can fluorescence-guided surgery improve optimal surgical treatment for ovarian cancer? A systematic scoping review of clinical studies

S T El-Swaify, M Laban, S H Ali, M Sabbour, M A Refaat, N Farrag, E A Ibrahim, R L Coleman

- 562** Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study



A D Santin, I Vergote, A González-Martín, K Moore, A Oaknin, I Romero, S Diab, L J Copeland, B J Monk, R L Coleman, T J Herzog, J Siegel, L Kasten, A Schlicker, A Schulz, K Köchert, A O Walter, B H Childs, C Elbi, I Bulat

- 571** Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer

A Andrikopoulou, M Liontos, E Skafida, K Koutsoukos, K Apostolidou, M Kaparelou, A Rouvalis, G Bleisa, M-A Dimopoulos, F Zagouri

- 577** Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse

F Brouillard-Saby, C Saint-Martin, I Ray-Coquard, L Gladieff, C Pomel, P-E Colombo, J-M Classe, M Chevrier, F Joly, T De la Motte Rouge, A Floquet, R Sabatier, E Barranger, H Costaz, E Leblanc, F Marchal, P Pautier, L Bosquet, M Rodrigues

Surgery

- 585** Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery

B E Swift, A Maeda, G Bouchard-Fortier

Reviews

- 592** Cervical cancer in sub-Saharan Africa: an urgent call for improving accessibility and use of preventive services

T Dzinamarira, E Moyo, M Dzobo, E Mbunge, G Murewanhema

- 598** Myeloid neoplasms post PARP inhibitors for ovarian cancer



G Caruso, F Gigli, G Parma, M Lapresa, S Derio, I Palaia, N Colombo

- 607** Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?



C Marques, F Ferreira da Silva, I Sousa, M Nave

Clinical trial

- 619** Phase II activity trial of high-dose radiation and chemosensitization in patients with macrometastatic lymph node spread after sentinel node biopsy in vulvar cancer: GROningen INternational Study on Sentinel nodes in Vulvar cancer III (GROINSS-V III/ NRG-GY024)

L T Gien, B Slomovitz, A Van der Zee, M Oonk

Tumor board

- 623** Association of nivolumab and niraparib in the management of neuroendocrine cancer of the cervix

O Touhami, M Plante, J St-Gelais, M Frumovitz

Corners of the world

- 628** The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization



D Tan, N Fujiwara, K Fujiwara, P Beale, J-W Kim, J Ng, S I Kim, A Evans, B-G Kim, on behalf of The Asia-Pacific Gynecologic Oncology Trials Group (APGOT)

Video articles

- 631** ECO-LEAK technique: early detection of colorectal anastomotic leakage by transvaginal ultrasound
V Lago, M Montesinos-Albert, B Segarra-Vidal, S M Cuenca, J J Hidalgo, P Padilla-Iserte, B Ferri, I Juarez, S Domingo
- 633** Post-operative ureteral injury after cytoreductive surgery for ovarian cancer managed by primary repair through minimally invasive approach
D Safavi, V S Subramaniam, N Obeidi, M Egan, F Abu Saadeh
- 636** Sentinel lymph node biopsy in open surgery for gynecological malignancies
L Boccione, G Candotti, R Cioffi, E Rabaioni, A Bergamini, M Candiani

Educational video lecture

- 638** Principles of urinary reconstruction in gynecologic oncology
E Chacon, N R Gómez-Hidalgo, V Lago, F Boria, J A Minguez, L Chiva

Pathology archives

- 640** Gynecologic manifestations of Peutz-Jeghers syndrome
S Bhardwaj, T Kalir
- 643** Sertoliform endometrioid carcinoma of the ovary
H Gupta, S Sancheti, P K Somal, A P Sali

Images

- 645** The fallopian tube origin of an ovarian carcinoma
J P Carvalho, G M Suárez

Commentaries

- 646** Cervical cancer screening: missed opportunities in a one-track model
E F Robinson, J P Darby, J K Moulder
- 647** Can simple hysterectomy replace radical hysterectomy as treatment of early-stage cervical cancer?
A Obermair, R Pareja

Miscellaneous

- 648** Correction: *The Effect of Adenomyosis in Myometrial Invasion and Overall Survival in Endometrial Cancer*